Martina Absinta1, Luisa Vuolo1, Anuradha Rao1, Govind Nair1, Pascal Sati1, Irene C M Cortese1, Joan Ohayon1, Kaylan Fenton1, María I Reyes-Mantilla1, Dragan Maric1, Peter A Calabresi1, John A Butman1, Carlos A Pardo1, Daniel S Reich2. 1. From the Translational Neuroradiology Unit (M.A., L.V., A.R., G.N., P.S., D.S.R.), Neuroimmunology Clinic (I.C.M.C., J.O., K.F.), and Flow Cytometry Core Facility (D.M.), National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD; Neuroimaging Research Unit (M.A.), Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan; Department of Neurology and Radiology (L.V.), University of Florence, Italy; Department of Neurology (M.I.R.-M., P.A.C., C.A.P.), Johns Hopkins School of Medicine, Baltimore; and Diagnostic Radiology Department (J.A.B., D.S.R.), Clinical Center, NIH, Bethesda, MD. 2. From the Translational Neuroradiology Unit (M.A., L.V., A.R., G.N., P.S., D.S.R.), Neuroimmunology Clinic (I.C.M.C., J.O., K.F.), and Flow Cytometry Core Facility (D.M.), National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD; Neuroimaging Research Unit (M.A.), Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan; Department of Neurology and Radiology (L.V.), University of Florence, Italy; Department of Neurology (M.I.R.-M., P.A.C., C.A.P.), Johns Hopkins School of Medicine, Baltimore; and Diagnostic Radiology Department (J.A.B., D.S.R.), Clinical Center, NIH, Bethesda, MD. daniel.reich@nih.gov.
Abstract
OBJECTIVE: To determine the frequency and nature of leptomeningeal contrast enhancement in multiple sclerosis (MS) via in vivo 3-tesla postcontrast T2-weighted, fluid-attenuated inversion recovery (FLAIR) MRI and 7-tesla postmortem MRI-pathology correlation. METHODS: Brain MRI, using the postcontrast T2-weighted, FLAIR technique, was prospectively collected in 299 MS cases and 37 age-matched neurologically healthy controls. Expert raters evaluated focal gadolinium enhancement in the leptomeningeal compartment. Two progressive MS cases came to autopsy after in vivo MRI characterization. Pathologic and immunohistochemical examination assessed the association of enhancement with leptomeningeal inflammation and adjacent cortical demyelination. RESULTS: Focal contrast enhancement was detected in the leptomeningeal compartment in 74 of 299 MS cases (25%) vs 1 of 37 neurologically healthy controls (2.7%; p = 0.001). Enhancement was nearly twice as frequent (p = 0.009) in progressive MS (39/118 cases, 33%) as in relapsing-remitting MS (35/181, 19%). Enhancing foci generally remained stable throughout the evaluation period (up to 5.5 years). Pathology showed perivascular lymphocytic and mononuclear infiltration in the enhancing areas in association with flanking subpial cortical demyelination. CONCLUSION: Leptomeningeal contrast enhancement occurs frequently in MS and is a noninvasive, in vivo marker of inflammation and associated subpial demyelination. It might therefore enable testing of new treatments aimed at eliminating this inflammation and potentially arresting progressive MS.
OBJECTIVE: To determine the frequency and nature of leptomeningeal contrast enhancement in multiple sclerosis (MS) via in vivo 3-tesla postcontrast T2-weighted, fluid-attenuated inversion recovery (FLAIR) MRI and 7-tesla postmortem MRI-pathology correlation. METHODS: Brain MRI, using the postcontrast T2-weighted, FLAIR technique, was prospectively collected in 299 MS cases and 37 age-matched neurologically healthy controls. Expert raters evaluated focal gadolinium enhancement in the leptomeningeal compartment. Two progressive MS cases came to autopsy after in vivo MRI characterization. Pathologic and immunohistochemical examination assessed the association of enhancement with leptomeningeal inflammation and adjacent cortical demyelination. RESULTS: Focal contrast enhancement was detected in the leptomeningeal compartment in 74 of 299 MS cases (25%) vs 1 of 37 neurologically healthy controls (2.7%; p = 0.001). Enhancement was nearly twice as frequent (p = 0.009) in progressive MS (39/118 cases, 33%) as in relapsing-remitting MS (35/181, 19%). Enhancing foci generally remained stable throughout the evaluation period (up to 5.5 years). Pathology showed perivascular lymphocytic and mononuclear infiltration in the enhancing areas in association with flanking subpial cortical demyelination. CONCLUSION: Leptomeningeal contrast enhancement occurs frequently in MS and is a noninvasive, in vivo marker of inflammation and associated subpial demyelination. It might therefore enable testing of new treatments aimed at eliminating this inflammation and potentially arresting progressive MS.
Authors: Cailin H Sibley; Nikki Plass; Joseph Snow; Edythe A Wiggs; Carmen C Brewer; Kelly A King; Christopher Zalewski; H Jeffrey Kim; Rachel Bishop; Suvimol Hill; Scott M Paul; Patrick Kicker; Zachary Phillips; Joseph G Dolan; Brigitte Widemann; Nalini Jayaprakash; Frank Pucino; Deborah L Stone; Dawn Chapelle; Christopher Snyder; John A Butman; Robert Wesley; Raphaela Goldbach-Mansky Journal: Arthritis Rheum Date: 2012-07
Authors: A Seewann; E-J Kooi; S D Roosendaal; P J W Pouwels; M P Wattjes; P van der Valk; F Barkhof; C H Polman; J J G Geurts Journal: Neurology Date: 2012-01-04 Impact factor: 9.910
Authors: A Scott Nielsen; R Philip Kinkel; Emanuele Tinelli; Thomas Benner; Julien Cohen-Adad; Caterina Mainero Journal: J Magn Reson Imaging Date: 2011-11-01 Impact factor: 4.813
Authors: Claudia F Lucchinetti; Bogdan F G Popescu; Reem F Bunyan; Natalia M Moll; Shanu F Roemer; Hans Lassmann; Wolfgang Brück; Joseph E Parisi; Bernd W Scheithauer; Caterina Giannini; Stephen D Weigand; Jay Mandrekar; Richard M Ransohoff Journal: N Engl J Med Date: 2011-12-08 Impact factor: 91.245
Authors: Martina Absinta; Govind Nair; Massimo Filippi; Abhik Ray-Chaudhury; Maria I Reyes-Mantilla; Carlos A Pardo; Daniel S Reich Journal: J Neuropathol Exp Neurol Date: 2014-08 Impact factor: 3.685
Authors: Julia O'Mahony; Amit Bar-Or; Douglas L Arnold; A Dessa Sadovnick; Ruth Ann Marrie; Brenda Banwell Journal: J Child Neurol Date: 2012-05-09 Impact factor: 1.987
Authors: Sung R Choi; Owain W Howell; Daniele Carassiti; Roberta Magliozzi; Djordje Gveric; Paolo A Muraro; Richard Nicholas; Federico Roncaroli; Richard Reynolds Journal: Brain Date: 2012-08-20 Impact factor: 13.501
Authors: Robert W Foley; Nathan T Tagg; Matthew K Schindler; Kaylan M Fenton; Daniel S Reich; Irene Cortese; Ellen M Mowry Journal: Mult Scler Date: 2017-06-22 Impact factor: 6.312
Authors: Erica L Eggers; Brady A Michel; Hao Wu; Sheng-Zhi Wang; Carolyn J Bevan; Aya Abounasr; Natalie S Pierson; Antje Bischof; Max Kazer; Elizabeth Leitner; Ariele L Greenfield; Stanislas Demuth; Michael R Wilson; Roland G Henry; Bruce Ac Cree; Stephen L Hauser; H-Christian von Büdingen Journal: JCI Insight Date: 2017-11-16
Authors: Céline Louapre; Sindhuja T Govindarajan; Costanza Giannì; Christian Langkammer; Jacob A Sloane; Revere P Kinkel; Caterina Mainero Journal: Neurology Date: 2015-10-14 Impact factor: 9.910
Authors: E S Beck; P Sati; V Sethi; T Kober; B Dewey; P Bhargava; G Nair; I C Cortese; D S Reich Journal: AJNR Am J Neuroradiol Date: 2018-02-08 Impact factor: 3.825
Authors: Jan-Mendelt Tillema; Stephen D Weigand; Jay Mandrekar; Yunhong Shu; Claudia F Lucchinetti; Istvan Pirko; John D Port Journal: Mult Scler Date: 2016-10-03 Impact factor: 6.312